← Home / Zenas BioPharma, Inc. (ZBIO)
Stock Analysis
Zenas BioPharma, Inc. (ZBIO)
ZBIO
ZBIO · Market data
31.44 -2.57%
Track ZBIO in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ZBIO price is:
52W Range Position
59%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 16:46 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 43.17. Holding above 26.17 keeps the current thesis intact.
⚖️
✓
Fundamentals
Weak / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
26.17
↗
Break Above
Confirmation improves above resistance.
43.17
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 26.17
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
13
●
Financial Results
HIGH
Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - - Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 - - Obexelimab global Phase 2 Sun...
8-K Filing • SEC EDGAR
What's Driving ZBIO?
📈 Technical recovery is improving
Momentum is Neutral. Watch 43.17 for confirmation and 26.17 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 26.17 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 2
Trigger
33.45
RSI(14)
60.6
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 26.17 and resistance around 33.45. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
ZBIO — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$2.0B
Company size
EV
$1.5B
Debt-adjusted value
P/E
-4.6
Not meaningful
P/S
196.1
Very high
P/B
5.8
Balanced
EV/Sales
154.0
Very high
EV/EBIT
-3.6
Not meaningful
P/FCF
-9.3
Not meaningful
FCF Yield
-10.73%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Long-term structure remains supportive
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Weak
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
0.00
↘ Weak
📈 Net Income
-80.99M
≈ Insufficient
🧮 EPS (Basic)
-1.46
≈ Insufficient
Zenas BioPharma, Inc.
Related Opportunities